Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.

iwCLL 2015

7 - 9 Sep 2015

Hilton Hotel Sydney, Sydney, Australia

Results of an analysis study into CLL mutations

Prof Catherine Wu - Harvard Medical School, Boston, USA

Results of an analysis study into CLL mutations ( Prof Catherine Wu - Harvard Medical School, Boston, USA )

Roundtable discussion on CLL: Expert insights from the iwCLL congress

Dr Paula Cramer, Prof Robin Foà, Dr Steve Coutre, Dr Constantine Tam

Roundtable discussion on CLL: Expert insights from the iwCLL congress ( Dr Paula Cramer, Prof Robin Foà, Dr Steve Coutre, Dr Constantine Tam )

Atrial fibrillation in CLL patients on ibrutinib

Prof Florence Cymbalista – University of Paris, Paris, France

Atrial fibrillation in CLL patients on ibrutinib ( Prof Florence Cymbalista – University of Paris, Paris, France )

Circulating levels of tumour DNA in plasma may help monitor treatment response and resistance in CLL

Dr Constantine Tam – Peter MacCallum Cancer Centre, Melbourne, Australia

Circulating levels of tumour DNA in plasma may help monitor treatment response and resistance in CLL ( Dr Constantine Tam – Peter MacCallum Cancer Centre, Melbourne, Australia )

Tumour specific immunotherapy in CLL

Prof Catherine Wu - Harvard Medical School, Boston, USA

Tumour specific immunotherapy in CLL ( Prof Catherine Wu - Harvard Medical School, Boston, USA )

Highlights from iwCLL 2015

Prof Stephen Mulligan - CLL Australian Research Consortium, Sydney, Australia

Highlights from iwCLL 2015 ( Prof Stephen Mulligan - CLL Australian Research Consortium, Sydney, Australia )

Cytogenetic and proteomic prognostic markers of CLL

Dr Lauren Thurgood - Flinders University, Adelaide, South Australia

Cytogenetic and proteomic prognostic markers of CLL ( Dr Lauren Thurgood - Flinders University, Adelaide, South Australia )

Predicting progression and survival in CLL

Prof Jonathan Strefford - University of Southampton, Southampton, UK

Predicting progression and survival in CLL ( Prof Jonathan Strefford - University of Southampton, Southampton, UK )

Phase I study of duvelisib in patients with relapsed or refractory CLL

Dr Susan O’Brien – University of California, Irvine, California, USA

$Phase I study of duvelisib in patients with relapsed or refractory CLL ( Dr Susan O’Brien – University of California, Irvine, California, USA )$

The LRF CLL4 trial: long-term outcomes

Prof Daniel Catovsky - The Institute of Cancer Research, London, UK

The LRF CLL4 trial: long-term outcomes ( Prof Daniel Catovsky - The Institute of Cancer Research, London, UK )

Expert panel discussion: The best of iwCLL 2015

Prof John Gribben, Prof Michael Hallek, Dr Michael Keating, Prof Kanti Rai

Expert panel discussion: The best of iwCLL 2015 ( Prof John Gribben, Prof Michael Hallek, Dr Michael Keating, Prof Kanti Rai )

Targeting the NEDD8-activating enzyme to induce apoptosis in CLL cells

Dr Alexey Danilov - Oregon Health and Science University, Portland, USA

Targeting the NEDD8-activating enzyme to induce apoptosis in CLL cells ( Dr Alexey Danilov - Oregon Health and Science University, Portland, USA )

Genetic deletions in CLL

Dr Carlo Croce - The Ohio State University College of Medicine, Columbus, USA

Genetic deletions in CLL ( Dr Carlo Croce - The Ohio State University College of Medicine, Columbus, USA )

High remission rates for new CLL treatment

Prof John Seymour - Peter MacCallum Cancer Centre, Victoria, Australia

High remission rates for new CLL treatment ( Prof John Seymour - Peter MacCallum Cancer Centre, Victoria, Australia )

CLL from a patient and physician perspective

Dr Brian Koffman MD – Medical Director of the CLL Society

CLL from a patient and physician perspective ( Dr Brian Koffman MD – Medical Director of the CLL Society )

The changing landscape of the young investigator meeting at iwCLL 2015

Dr Giles Best and Prof Arnon Kater

The changing landscape of the young investigator meeting at iwCLL 2015 ( Dr Giles Best and Prof Arnon Kater )

Ethnic variations in CLL prevalence

Dr Thomas Chan - Queen Mary Hospital, Hong Kong, China

Ethnic variations in CLL prevalence ( Dr Thomas Chan - Queen Mary Hospital, Hong Kong, China )

Risk of bleeding-related adverse events in ibrutinib treated CLL patients

Dr Adrian Weistner - National Heart, Lung and Blood Institute, Maryland, USA

Risk of bleeding-related adverse events in ibrutinib treated CLL patients ( Dr Adrian Weistner - National Heart, Lung and Blood Institute, Maryland, USA )

Crystallography of the B-cell receptor immunoglobulin in CLL patients

Prof Paolo Ghia - San Raffaele University, Milan, Italy

Crystallography of the B-cell receptor immunoglobulin in CLL patients ( Prof Paolo Ghia - San Raffaele University, Milan, Italy )

Epidemiology of CLL: Interlymph consortium and genome-wide sequencing studies

Prof Claire Vajdic - University of New South Wales, Sydney, Australia

Epidemiology of CLL: Interlymph consortium and genome-wide sequencing studies ( Prof Claire Vajdic - University of New South Wales, Sydney, Australia )

Harmonisation of CLL diagnosis and detection of residual disease monitoring by flow cytometry

Dr Andrew Rawstron - St James Institute of Oncology, Leeds, UK

Harmonisation of CLL diagnosis and detection of residual disease monitoring by flow cytometry ( Dr Andrew Rawstron - St James Institute of Oncology, Leeds, UK )

Primary results from the MABLE phase IIIb study

Dr Anne-Sophie Michallet - Centre Hospitalier Lyon-Sud, Lyon, France

Primary results from the MABLE phase IIIb study ( Dr Anne-Sophie Michallet - Centre Hospitalier Lyon-Sud, Lyon, France )

Results of subgroup analysis of the HELIOS trial

Dr Paula Cramer – University of Cologne, Cologne, Germany

Results of subgroup analysis of the HELIOS trial ( Dr Paula Cramer – University of Cologne, Cologne, Germany )

Results of a new phase Ib trial of voxtalisib in combination with chemoimmunotherapy

Prof Farrukh Awan - Ohio State University, Columbus, USA

Results of a new phase Ib trial of voxtalisib in combination with chemoimmunotherapy ( Prof Farrukh Awan - Ohio State University, Columbus, USA )

Highlights from the iwCLL conference: B-cell receptor Btk, PI3K and multi-molecular BCR inhibitors

Dr Amy Johnson – The Ohio State University, Columbus, USA

Highlights from the iwCLL conference: B-cell receptor Btk, PI3K and multi-molecular BCR inhibitors ( Dr Amy Johnson – The Ohio State University, Columbus, USA )

A laboratory model of the hypoxic tumour microenvironment

Dr Giles Best - Royal North Shore Hospital, Sydney, Australia

A laboratory model of the hypoxic tumour microenvironment ( Dr Giles Best - Royal North Shore Hospital, Sydney, Australia )

Will chemotherapy remain the cornerstone of CLL management?

Prof Clemens Wendtner - Klinikum Schwabing, Munich, Germany

Will chemotherapy remain the cornerstone of CLL management? ( Prof Clemens Wendtner - Klinikum Schwabing, Munich, Germany )

New research into new small molecule IKKα inhibitors

Dr Elaine Willmore – University of Newcastle, Newcastle, UK

New research into new small molecule IKKα inhibitors ( Dr Elaine Willmore – University of Newcastle, Newcastle, UK )

Phase II study of idelalisib monotherapy in older CLL patients

Dr Andrew Zelenetz – Memorial Sloan Kettering Cancer Center, New York, USA

Phase II study of idelalisib monotherapy in older CLL patients ( Dr Andrew Zelenetz – Memorial Sloan Kettering Cancer Center, New York, USA )

History of the B-cell in its 50th anniversary year

Prof Max Cooper - Emory University, Atlanta, USA

History of the B-cell in its 50th anniversary year ( Prof Max Cooper - Emory University, Atlanta, USA )

Human B-cell receptor structure and function in CLL

Prof Freda Stevenson - University of Southampton, Southampton, UK

Human B-cell receptor structure and function in CLL ( Prof Freda Stevenson - University of Southampton, Southampton, UK )

Translational research and the future of CLL treatment

Prof Steven Coutré – Stanford University School of Medicine, Stanford, USA

Translational research and the future of CLL treatment ( Prof Steven Coutré – Stanford University School of Medicine, Stanford, USA )

The role of CLL cells, T-cells and macrophages and their effects on the tumour microenvironment

Prof Arnon Kater - Academic Medical Center, Amsterdam, The Netherlands

The role of CLL cells, T-cells and macrophages and their effects on the tumour microenvironment ( Prof Arnon Kater - Academic Medical Center, Amsterdam, The Netherlands )

More from ecancer